

August 31, 2022
 Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President and Chief Executive Officer
 (Securities Code: 4582)

Notice of Appointment of Corporate Officer

TOKYO, Japan, August 30, 2022 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, the “Company” or “Symbio”) today announced the appointment of a corporate officer by the Board of Directors on August 30, 2022.

Appointment of Corporate Officer

Effective on October 1, 2022, the Company established the Global BCV Business Unit, and appointed Mr. Kei Bamba as Corporate Officer and Head of the Global BCV Business Unit.

By establishing the Global BCV Business Unit, the Company aims to develop a more agile global business by building a seamless process from research & development to commercialization.

Statement from Mr. Fuminori Yoshida, President and CEO of Symbio: “For the Company, the successful development and commercialization of BCV means the globalization of our business. We expect that the establishment of Global BCV Business Unit, which is an integrated system, will provide a strong driving force for the globalization of the business.”

1. Newly appointed Corporate Officer

Name	Title
Kei Bamba	Corporate Officer, Head of Global BCV Business Unit

2. Date of Appointment: October 1, 2022

3. Profile of the newly appointed Corporate Officer

April 1999	Pfizer Japan Inc.: Started in the Sales Division, Director of Marketing Excellence in Products Business Unit and other position
November 2013	Eli Lilly Japan Inc.: Director of Marketing in BioMedicines Business Unit

March 2017	Bristol-Myers Squibb Inc.: Director of Sales in Specialty Business Unit
July 2018	GlaxoSmithKline Inc.: Corporate Officer, Head, Specialty Care Business Unit
April 2022	Amgen Inc.: Corporate Officer, Executive Director, Head, Specialty Care Business Unit
October 2022	Joined Symbio Pharmaceuticals Limited as Head of Global BCV Business Unit.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About the Anti-viral Drug Brincidofovir

Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved and marketed in the United States and the European Union, but unapproved in Japan. As BCV exhibits not only higher anti-viral activity, but also a superior characteristics profile in comparison with CDV and other antiviral drugs, BCV is expected to be an effective treatment against a wide spectrum of dsDNA viruses such as herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BK virus, papillomavirus. Moreover, BCV is expected to be a highly active antimultiviral agent that can reduce the risk of nephrotoxicity or myelosuppression, which are serious side effects of other antiviral drugs including CDV. Symbio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants Symbio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of orthopox infections (which includes smallpox and monkeypox).

The Company is expanding its business aiming to become a global specialty pharmaceutical company by 2030. To maximize business value, the Company is currently conducting a global Phase II clinical trial mainly in the U.S. for patients with adenovirus infection after hematopoietic stem cell transplantation, and initiated a global Phase II clinical trial mainly in Australia, Japan, and South Korea for patients with BK virus infection after kidney transplantation in June 2022.

In addition to its high antiviral activity, BCV is also expected to have anti-tumor effects, and we are currently conducting joint research with the National Cancer Center of Singapore, the University of

California, San Francisco, and Brown University in the U.S. to confirm BCV's anti-cancer activity and synergistic effects when combined with its antiviral activity. Furthermore, the Company has initiated a study to evaluate the potential antiviral activity of BCV against EBV in collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) in the U.S.